<SEC-DOCUMENT>0001193125-13-011362.txt : 20130114
<SEC-HEADER>0001193125-13-011362.hdr.sgml : 20130114
<ACCEPTANCE-DATETIME>20130114090128
ACCESSION NUMBER:		0001193125-13-011362
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130114
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130114
DATE AS OF CHANGE:		20130114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35647
		FILM NUMBER:		13526706

	BUSINESS ADDRESS:	
		STREET 1:		9815 S. MONROE STREET
		STREET 2:		SUITE 100
		CITY:			SANDY
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		9815 S. MONROE STREET
		STREET 2:		SUITE 100
		CITY:			SANDY
		STATE:			UT
		ZIP:			84070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d466697d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): January&nbsp;14, 2013 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>LIFEVANTAGE CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Colorado</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-35647</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90-0224471</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other Jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9815 S. Monroe Street, Suite 100, Sandy, UT</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>84070</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;432-9000 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;14, 2013,
LifeVantage Corporation (the &#147;Company&#148;) issued a press release regarding its operations in Japan. A copy of the press release is attached as Exhibit 99.1 to this report. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information furnished in this Item&nbsp;8.01 and the exhibit hereto shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release issued by the Company on January 14, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: January&nbsp;14, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LifeVantage Corporation</B></FONT></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rob Cutler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rob Cutler</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d466697dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g466697img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LifeVantage Launches Protandim, the Nrf2 Synergizer in Japan </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>In Country Operations Formally Underway </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SALT LAKE CITY, January&nbsp;14, 2013</B> &#150; LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business
opportunity and scientifically validated products, including its patented dietary supplement Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the
Nrf2 Synergizer<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, today announced a significant milestone in its global expansion: the Company&#146;s release of
a new formulation of Protandim in Japan with potent Nrf2 activation as well as the implementation of necessary warehousing and product fulfillment resources to be fully operational on the ground in Japan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internally directed research and development programs have enabled LifeVantage to produce a formulation of Protandim for the Japanese market that meets
recently enacted local regulatory requirements. &#147;As part of our ongoing Global R&amp;D program at LifeVantage we conducted a proprietary cell bioassay test that allowed us to identify an ideal formula for Japan that causes significant Nrf2
activation,&#148; said LifeVantage Chief Science Officer Dr.&nbsp;Darlene Walley. The formulation being distributed in Japan is the subject of a placebo controlled, double blind clinical study being conducted at Colorado State University.
Preliminary data from that study show the product to be a potent oxidative stress reducer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Today we celebrate the
launch of a full-bore sales and marketing program in Japan, a nation of 130 million,&#148; said LifeVantage President and Managing Director Asia-Pacific David K. Toda. &#147;We already have an established base of independent distributors in Japan,
and their enthusiasm for Protandim and TrueScience<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Anti-Aging Cream has been extraordinary.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This is a historic day and a major milestone for LifeVantage,&#148; said President and Chief Executive Officer Douglas C. Robinson. &#147;We could
not be more pleased with the significance of this day&#151;moving from a NFR status to a full-business operation in Japan. It is the culmination of two and a half years of dedication and commitment from our corporate team, our network of independent
distributors and business partners and allows LifeVantage to realize its mission of providing extraordinary health products to the people of Japan.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About LifeVantage Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">LifeVantage (Nasdaq: LFVN), a leader in
Nrf2 science and the maker of Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2 Synergizer<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging
internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 and is headquartered in Salt Lake City, Utah. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This document contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism and satisfaction with current prospects, as well as words such as &#147;believe,&#148; &#147;anticipates,&#148;
&#147;look forward to,&#148; &#147;should&#148; and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited
to, statements we make regarding our global expansion, including in Japan, and our new formulation of Protandim for the Japanese market. Such </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g466697img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">forward-looking statements are not guarantees of performance and the Company&#146;s actual results could differ
materially from those contained in such statements. These forward-looking statements are based on the Company&#146;s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and
uncertainties that may cause the Company&#146;s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the Company&#146;s inability to successfully
expand our operations in existing and other markets and thereafter manage our growth; the Company&#146;s ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the Company&#146;s ability to expand
its product offerings; violations of law or our procedures by the Company&#146;s independent distributors; the potential for third-party and governmental actions involving the Company&#146;s network marketing efforts; the potential for product
liability claims against the Company; the risk that government regulators and regulations could adversely affect the Company&#146;s business; future laws or regulations may hinder or prohibit the production or sale of the Company&#146;s existing
product and any future products; unfavorable publicity could materially hurt the Company&#146;s business; the Company&#146;s ability to access raw materials for its Products as it grows; and the Company&#146;s ability to protect its intellectual
property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk Factors,&#148; and in
other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking
statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this
document, except as required by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cindy England (801)&nbsp;432-9036 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor Relations </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">-or- </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Mills (310)&nbsp;954-1105 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Managing Director, ICR, LLC </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g466697img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g466697img001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`'P#(`P$1``(1`0,1`?_$`,````$#!0$!````````
M``````@!!PD``@0%!@H#`0`!!0$!`0`````````````&``0%!P@#`0(0```&
M`0,#`@0$`@<'!0````$"`P0%!@<1$@@`$Q0A%2(6%PDQ02,D81E1@3(T)348
M0E)CDT2TM28V=C=W$0`"`0(%`@,#"`,,!@L````!`@,1!``2$P4&(0<Q011A
M(A51@3)"4B,6")&A%W&QP8*R0R2T-75V-V+"4W.#)I+2PS1$)38G&"@X_]H`
M#`,!``(1`Q$`/P#W\=+"Q'7RV@LE94K$/,8NEO9,CXGM[>_X[9@N+=E,2L4F
MNU/$21U52-E'#]FJ<J1E=J(F,9$PE36.8+Z[?MLO''N+3=XM;:]RM#;W#$59
M%8A@Z4%0%8#,!4THW5E`QF#NK%R'EJ6>Y;#-Z?>MFOQ=6J@T61E#(R/4T+,A
M.4M1:U0T5V..@P1R\1SG%KLV3AM6<GUHI&.2L1SC,K&\T.<1`$GA7L"[[4JY
MK[A8HJ,I!-([==`Q0$P*`8@#^\<(V[9IR)`TEBW6*=7K'*GD0P]T/2@92:@^
M'3!9LG<;==YM@P98MP4`2PL@$D;CZ0*GWBM?HL!0CVXSN+7-2F\G;+DJOT]"
MP%4Q9;FU+L_S!`$A=TA(QCN6B9&&<-WKQN]8O6S%4%$5!2>-A*7O))@=/>TY
MGP&3BMNK7&59V0NN5\X(#*K`U`H06%"*JW6A-.C[M_W/3F=V8[?,UN&"DM'I
MD9E9D84)!!"FJFC+TJ!T!V_+3.%]P].X'84I>(1;9`OQJ]9`E(L)$ZL:#J`1
MVLC^0AX:^R15^/0WJ(>GIU,=IN$;#S"PWZXWI9FDV^PU8<CY*/EE/O"AS#W%
MZ=,"??[N=ROMWNG%;3C3VZP[MNIM[C5BU"8\T`HAS+D-)&Z]?+ITP9_5,8TC
MCCPR#1QN8X["V0`WL(_W8:A[HT^80C-A5//&*[GE^)VS@;?MVZ#U,?A_?/@W
MXB])<?`M33]1D;2SUIESTRYJBE*UP/?BWC!Y'^$!?VGXI$.KZ347U&G2N?2K
MGRT(.:E,!0ZY`9YR/R6G,689@ZTUH6*+#"LLE2T^F0TE),3/T&\[X:ZSD$FI
MA`KA-DBBD993QS*G4*`@F%U1<`X'QSMI!RGF<]RV_;M;R-9QQ'W$;*3%F`6K
M?4,C,V49P@4D%CFFX[L]U>8]Z+K@O;BULH^+;#=PIN,LX!DD3459\A+44TU%
MA1%+MIM(S@$()!Q'3U'T`/41'\NL^XUOX8M*8IR@8ABF*/J!BB!BB'\!#4!Z
M]((-#T./`P89E(*G`-XTY)9`#FSG3B1F..JL:5&C5;.G&*Q0+&1C%;[B%ZL%
M5O\`#SPR$S*MG]UQQ?4B)N3-2M06CY!NL+<A=3F,]QX]8_@ZRY3M+2M69[:\
M1B#ISCWXV6BJ1'+'U&:M&4KF)Z8"=MY'N'XSO>*;PL2@0I<V;J&&K`3DD5B6
M8&2.3H0*$K[V4#K@YN@O!O@'<'<D+YGCE;R=I=58U8.-?&WY7Q*K;0CY1:TW
M?D>Z:A9LC1<1,>ZEAD:GB^`?1\:]1%@+A68='VK]M(2"9[UQ^QV3C&W7=R9?
MQ#N&>?)49([0')$67+FSS,&=3FH$'5:G`1LG(K_?>5;E9VHB_#>W9(,]"7DN
MS[TH5@]`D*T1U*`ER"&*X.#<7=LW%WZ;MNH;MNNF[;^.FOY]!E//RP;5%:>>
M+NECW%=+"Q72PL`!.Y9R0V^Y]C_"#:T/4\32W"B^9,DZ:5I'&8.;W%9EJU:C
M[&H],R-*D<M81^JV!,K@J`E4U%,3:&`[@VO;F[:W&\M$/BJ;S%"LE341M;NY
M2E<M"P!K2O3QIBNKC>-S7NK;[$LK#:'V.6=HZ#*95N50/6F:H4TI6GLK@_\`
MH$Q8N$`0'\!`?R]!U]0_+I86%Z6%A-0UTU#73737UT_IT_HZ6%A>EA801`/Q
M$`_+U'3UZ7CA87I86*Z6%B%;D/R<RZ[O<UQWX64*!RCGF/`5+W>;FZ49X4P*
MV>G/XJUXE6YB^]6Q4NIDH=`YE"::'364`R`:'VC:-O%I%NW))I+?9V`R)&*W
M%Q0==,?53_3\_(J.IRKOV];HUQ-M/%88Y]Z4G,\AI!!4]-1AXM_H#P\P3[N`
M=^E?(0<Z57C]S+NV*>4^1\NXZR/E/&&3X"@ML>V[!%AQI%%DZ]7\>VN`BJM8
M2Q<I+Q:J:R1A21T7(J7:8IP5-;2]X_%MR[_LEM/8;=;7T<%Q"\FI'<Q2E%9I
M4+.M5#YP?I5%#Y4`9[/D#;T..\BGM]PO[BR:>"98Q');2QB0KI.JHWO9,A'1
M:',*&M9V<0NHJ37JD]#LF+)"SHHV1UX+)JQ%W(RL6"SUV_*U11\F3%8!(NJJ
M`JF,GH8?3JG.46\EI:7=I*27A8IU)-`K@`"I-%I0@#I0],7OPZ2&?<+.Z@"J
MDOO]`!4LA))I3K7Q)ZU\<,+]P7_W5Q2__63_`/?U'H\_+]_97*_[I_U9\4]^
M;?\`MW@?]_G^7:8DLZS5C:6`B+;*`/.A:H!BYH7(7TS,^'*_S3*B[&*\!L?V
M3Y4\;VD"=L0)W^[W/AUT]>KN.T[^.QB[N=T;\/?$\OH="/+GSM][KYM3QZY<
MM.N,RKOW%#^:%N/#8XQR[X)G^*>IESZ613H^ERZ5*$#/FS=*TP$7&+!-B>\H
M,DQ9,LV1JKA.[Q4A/R!"2O>R>DQFWA%&E@VV=,Y$G/BB)A='D0_4'4H^NMV]
MSN=[=#VPVRY.TVSKO=C(L252ED7C6C1?<D$KFZ9!#X>(QF7LGVMWBY[W;U8+
MO]Y')QK<XI)Y`):[D$F<%9_Z2"`V4UU&N![QZ'SW<A<HOEUD^\*Y6SJRQ'@Z
MES:T#5:2WM$;7Y2W^*NJF$LN@^7[#@JZ:/?6=+I.02%9-!N0HD44!C;[-<]H
M^+V*<5V)]WYQ>PB6>Y,+RI;Y@/NP5%10G*J*R9LK22$@JN)*\Y%8_F!YON<G
M/.4Q\?[8;;<F"ULUN8[>6[RL1JLKG*V8+G>5UD"YUBA52KN-1<D:IQ2>1.4.
M+_(9C=8=I+,6]PQ%*W2(L!IN+<J%267;M8Y1ND](80V**`V*[9[RKIK"0AR=
M/-F?=>ZT4W%^Y_'I+*]>)C;WZ6\D6E(HJ`6<$K\H&<QR4*,E6#88<CCV'L-<
MV_-^R/+HMRV]+A%N]JEO(I]:)B`2JQE0X^JS:8EAJ)4DRJRX=?[B4?+%Q1@G
M[AV'8IW+7_A],,,X#%1Y?\4O7&ZZPC9CR`QZ8I"Z.#/<=N_=VY3;NT]ATS)A
MO'0<^<-B6SW[<NW&^,$MMP+VA8_1CO(7/IY?FE7(?E5^O3&S^7W7Q;C6T]TN
M.*6GLDBO5'G)97$:M<1'J`*PL'J?HY"1U."#Y8\OX'"_#:<Y)8X5:WB6NU3J
MK3CK%,13<_4G)&82Q\5AJ)C&X[A?HS$S/M'*Q"@(E8)+''0""(#?%^*3[ORU
M./;@##%#*YNB>FE%!4SDGRHJE0?M%1YX+>4\NM]IX>_(]M(FEGA06@`KJRS@
M"``?6J6#$>.4-\F`()C?+6`,?\.?M?X+R8[HN;,Z062,T<JN2L2FVD+M7Z[$
M/HRQYUO-17DTUB*Y(RKD^])PL%(N$UQBV8'7V`9NCM-SN&V;Y?;MW(WJW$^S
MV3Q6]G:-41NS`K;QN%\(H8H]21`1G8TK[QJ!#;MUV&PVCMGL=RT&]WR2W%[=
M@YI$12&N'0L<QDED?2BD.8HJBM*`@F2_9\X&A$;#XTN*M_\`A>?75;,V75,^
M?,94P`EN#*PW3YD)/$<`"P`!P8@<-OC]K]/H=_:OS;5Z7$0L?#TVA!Z;)]C1
MT\N6G3[5/K5ZX)/V/\#T\WI9?B.;/ZG7G]3J?[35U*YJ]:4R>62G3$=%1DK?
M5_L<<YBGR'?[+9*/=^8U<C,@V:UR\A?7:=5S1.0L;*/[*1RB_"4.W9E,H9`R
M)`.8VPI"CM"P+N*UN>\VR_<01V\T-BYB1%$0SP!B`GA2IZ5KBN;&:\MNR.]D
MW%Q)<P7%ZBRNY,IR3Y02_CFH.I\S7IU.)#<=?:UX@6.B5*=S;3[/R:R+,UB$
MD9_*7('(-XR!<)&1D(QLZ<N(I-[820-):$55T0:0;2/00(4N@&.`J&`=P[E<
MKM[Z6#9I8]NL$E8+#:Q1Q1@`D#-1<TA^5I&8GKY=,6%M?:WA]SMT,^]PR;GN
M#P*7FNY99I"6`)RYGI&*GH(PM!3Q(KCG>.4"^P9S2SIP0B[E?+EQRFN,=2S[
MCRN7^Z62VV7$#JQ7NSXQN>/:E?YJ2>7=S1)5NV;/X]%Y(+N8AP"I6ZQ2'`"N
M-_F3>>'V7-Y8H(M_3<GMI6BC1$G"1I-'*\2@1B122K95`<4+#IAOQ]3LW-;[
MM]')/-Q]]J2ZB625W>#/(T#PI(29,AIG4ERRGZ)'4D.IS[<W%-I]T#'F%D*Y
ME,,?R?".^Y!=,3\D^2"LZ-GC,SU:`:+H7-7*Y[FUB@C'BA3QJ3\D<JJ(+'0,
ML4IP+H.X')V[:7&[F2V]<N\Q1`^DM,N0V[L1IZ.F6J![Y4N!T#4Z8"+GMSQ1
M>[-MM`BNO0OL4LI'K+O-G%RJBDFOG"T/T`P0GJ5KUP_--PZ'-?*F5,&K7+)-
M'X`<)+%%\:X3%5/R/>H:S\B,KU6M0LC?G.7<H#.J9+F<=8]3EVL.UCBRQ59A
M^5PZ>KJ`0B9H*\W8\/VVUWH0V\W.=XC-VTSQ1LEK"[L(M"'+I+++E+LQ2B+1
M545K@GLMI7FNYW>Q:T\/`MFD]&((Y95>ZF1!K"XE)U6BCS!%`>KFK%JBF&A^
MY1]NGC!QVX:9LS?QH@+IQOR!0*[`.Q>88R=D"H0]WBU;A78QY6\AUU.Q.(:T
M13MN_.?O*)$?I+D(<C@``Q#R_;OG_)-_Y?9[-R)X=PL)Y'%)X8G:-M-B'B;(
M&1@0!0'*149?`B![G]N^,<;X5?;]QF.;;MQMXX^MO-*BRKJ*N25,Y#K1R:]&
MS`',:4)L<MLDY>NF0^-O!_`]WE<4V_/M5M61,N9L@T47%OQ;Q_QJUK[*T+X]
M.^0=,662+[9K,PAHV2736+$E56=`F98J)BAO%]NVJTL=QYEO4*W-K8RI%!;M
M]":YE+%!+2A,4:(SN@(ST"UI4$\Y3N6ZWE]MO"MDF>UN[^%Y9[A?IPVT04/I
M$^$LC,$5Z')XTJ00@_9^X'#$`0,9W`+\&CP,ZAF3+@Y\"Q@GH%M#*QKH:R^_
M>1^MIO\`"W?!X_9_2Z7[5^;:O_>8O0^'IM"#TV3[&CIY<OE]KSS5ZX^3V?X&
M8ZFUE^(9LWJ=>?U.I_M-;4KF\Z4R>63+TP)W&7D5/\0OM5YDRL^EK%F.[8TY
M$\F,9T1WDJRN)&:OE[D.55JQ'C0MRL3M8ADVTC8Y)BK)K$,@D@V[YDP2(4-I
M/R'88.6=S+3;42.TL[FPM)I!$H"QQBS2:7345ZA`P0&I)H#7`WL&_P`_#.V-
MYN4LDM[=VM_<PQM,U7DD:Z,,6HU1TS,I<U'0$U'CAQ:?PDX17:*;W#F_FZB<
MQ.05@:^;>+KD?-I"4>`F)!)-21KN',8Q%QB:;C>D0RX"A'IM&19`R*93N'!U
M!';'W7,>9V<AM.'6<^U;%&:1QQ6_WC*/!YY6C9Y9&'5LS9:F@%/%W;\,X+?H
M+WFE[;[MOTBG4DENONT+4S)!$LBI%&M*+E4-TK4>`U5/GZ[P/Y,8$H.&<^?5
MCAQR@NY\*_1ZR9:;Y8L7'#,DC!3%@QS-8TL<O.SEV^E5U+7G40^B'SARWC'Z
MC=9!4H+`AUVNX+CFW';Z^W>Q-MRW;8?4:Z0&%+J`,JRK*JJL>M'G#JZ@%E!!
M'0G'&TNK3@O)+"PV?<%NN(;E,+86[3B9K2<J3"86+-)I292C(Q(5O>S$D#$C
M7)S)%PKT)6\5XC6;$S?FZ2=U&A/'*9UV=*BD&ODW3*DP@F`F-%4"#.*Z91_O
M$BJU0`#=P0Z#>(;-9WDL^][T#^'=M023`=#*[&D-LI^U,_0_9C#MTI@PYSR"
M^L([7CFP%?Q5NTC105ZB&-1FN+MQ]BWCZC[4K1I0YL#K"X&F\&8Y)0,$.HN(
ML4,Z?3,BYR%"KS#++%N>F[TM/9%GX\[>RM96SN]3>YLUE/"*<H`@LBF"75@G
M>[7>9SN>Z#4250!I/E:!`/=2)#5"J>!1U!8BN92<50W'K_8X!MNU,8YH68N)
M8\XN&/B\KCWPS^(=&H*]58"@C:IN?8SD#]QKC:\3JUAH.0<7X\Y'8MS#C*R)
M&/-8]R/`PSMZ]B222"23.PP,G&/V[^*DVP`F\8.$SB1,^X@'5SM<FU]O[K/)
M%-97%Y!+#*A]V2)C$`U#]%@05=#6C`]2,5O:[NF\]R[3+%+#>VUK-#-$ZD-'
M(@GJ`:>\A%&1QT(/D01B;G&M=)&SK9*+8KMV))"5EW!!!;Q6BTF=PZ>>."GP
M-4'+]P90J)-"`HJ<2@`#Z5'R6_$NW.;B16F9$1?"K!:`5IU)"BA8]:`5.+WX
MEM[Q[O%Z>-A"KO(W0Y5S`DTJ*`%C4*/,FF!8^X])I0DAQKG7*#IPT@LARLR\
M29(]YR=K%&K#]P1`@F33%=1%N8"`8Q"B;340#UZLW\N-L]];\EL8F59I]N2-
M2QH,SZRBI\:5/6@)IX`XH;\Y%['MEWPS=)E=X+7=Y9G""K%8O3.P4=!F(4A0
M2`3XD>..UC?N187E).,BT*9EHB\K)1\6W46KU=*B1>1>(,D5%C$MISE1(JN`
MG$"F$"@(@`_AU"7/Y;^:6MM+=27FTF.*)W-)IJD(I8@?<>-!T\.OG@FL_P`Y
M7;>]O(+&+;=_$L\T<2DP6]`TCA%)(NR:`L"2`32O0XY],!_F<+>AM/HT;UVC
MM_RMG_M::=2+T_\`C&OR_&?]=L1*?_MEO'_TY_V287BH33EWS,*(")36)`?B
M*(`(*3DJ80`1]!#XM.OGNJW_`+1\,(\?3']4:878A?\`[!=QU/AZQ?+Y9Y3@
M:7]#H'%?*MUB>0>$DLC8?MLTYF:'DA"$++N(!LY655+#N5%%FK8"MDUBI.&I
MU$UR*)`NB58BP@%E6^^[_P!T^*V5WV^WL[=S"TA6.ZLS)IB5E`&HHHQZD$HX
M!0ALCE"F*7N^*\4[%\[W+;^[?&5WCMY?W+36.XK#JM`K$G28ED7W00LD197#
M+JQB19,.QC6<X@9CRC#4?&'%$]DK#IH]/8,@&K*,?%UM=-,JC-5XU4<J"6,4
M,!DE5%54'`*G3!)%8!,("?);'N_P[C$V^<HY6+;<U==*UUB[S`FC!6`'OCHR
MA59<H8NZ=*GW"]S_`"]=Q><6W&.$<#-[LCHYGO\`TXCCMV`!0NI8_='JK,[H
M^9D$<<@)I*.VJ]=:5A"EMX6.)4V\&2LI5X6R:D46OIL`BR0YF:H'24C_`&X.
MR*9@$HI_".H=9;N=PO;N_?=+F5WW&24RM(3[YD9LY<G[18YJ_+C=%EM6V[=M
M<6R6,,<6T00+!'$H]Q840(L87[(0!0/DZ8\_O$_BSFI'F)7^*V3H]TZXD?;)
MM=KS1QYF'XO'!<C/\Z'D5^.D/)J.2E;2"G&ZMKV5H@JB83(/$FV\H:)CU=W)
M^2[-^$WY+MK`<IY%$EO=**#1%O0716G@+IM(D'Q4M0^.*+XMQC?3S%>,;JI/
M$N.2O<6K&IUS<>]:YBU0QMAJT92,KC*1E(P='-NK9"Q+G/CUSWQI0I_*C'!]
M?R)B?D)CBF,3R^0IK`&3UJ]*NKECV#*H0]ALN*K;5VTFI%H_N9*-7=)I?J$)
MH%\.NK#=-EO^$;C.EL]Y)%/:RR'+$MS#F7)*WU5F1R@<]%8*3XX.N96=]MF^
M[?SK;H&N5LHY8+J)%+2M;2Y3GB`\6A=0Y4"K*3U`!(ZXGW7?MT'IOSK_`*O,
M-$;`AW!JJEE(GE$'G<['L@XB.B&3_F3R?T_;@B?,$_H">GKTT_9ESWUGHOA=
MWFK3/E^YIXYM>NCEIUS9\OMP\_:CP#T/KSNEKDRUR9CK>-*:%-;-7IER5KB)
MBHV!G;OL0<];9&-I1K'6F^<TK)&M)F,<Q$TWCYW-\_*,D9:(=%!W&2:;9T4%
MVZ@`H@J!B&]2CU:EY`]KWMV2UD*F2."P0E2&4E;=02K#H14="/$=<4_8W$=W
MV*WVZAKI27-\PJ*&C7%14'P/RCR./1_CK_Z^HO\`\-K'_A&/6?-P_M"?_?/_
M`"CC1^U_V9;?[B/^0,1WPFO\Y>^^@Z?RXZ-ZZ#MU_P!1=G]-W]G7^'X]'TW^
M4,'^(9/ZHF*VM_\`.ZX_PS'_`%QL?.R@/\Y7%@Z#I_+NR9Z[1VZ_7^F^F[3;
MK_#\>O;;_*&Z_O\`A_JLF%=?YVVG^&YOZVF&YCLEL/MK<D>1"&>&TS"<0^5V
M5UL_8]Y"HQ<K-4O$^8K?"1$1E#%>9'D6U>*TF.LLS`)S%>F'*2<6=-RNV77(
M=#4'LFWR=P^/V!V4H_*=KM1;2VI95DF@C9C#-`&(U"BL4E0$O4!@*''"&^B[
M;\AW'XT'3BNZWGJHKFC.D-Q*`LL,U*E`[*&C;*%`)!)]XJR_W6ON$\,<@<(<
MW8BQ9R&QSF/(N1ZY"1]?K>&YUKE-9FBVNM5?/)NUO:0>:BZ9763='51[*+M$
M3&,4B8G4,4@S/:_@G+;'F=ENNY6%Q:;?;R,6>=3#6L;@*@DRM(Q/U4#&@)-`
M*X@.[W/.(7W!+[9]NO[>ZW"Y10BP-JTR2QEB[1YEC`I2KE:D@"I."FY<UW(N
M'LL\9>>N-Z3:,IP^&:'<L/\`(;&='8C+WV4P)DTE7G7-XH4$38O9)[&%RJ+*
M2<120BXD8XZP(Z*)!N&N+W%ANNV;EPC<)H[:6[GCGM9I#EC%S#G41R-X*LT;
MLH<]%:E:UP6\IM=PVG=-LYSM\4ES#9V[P74,8K(UM*$8R1KXLT3H&*_6%.J@
M%@XQ?NN?;I/3@NA.7>&S-Q0`X50+*0<HF>"IV`@RXA[/U/&R"Y_3".")\P3^
MG;T]>HX]LN>B[]&=KN\U:9\OW-/'-KUT<M.N;/EIYXD_VH\`]%Z[XI:Y,M<F
M8ZWC2FA36S5Z9<E:^S$=_'C!BO./[16<\?TP&\;/9%Y*<H,FXR;WZ$\=F2UU
M[EQ;,JT6"OM>DTE3,X^7D(EO&S;-PF<R+=RX24(82B43W?=Y'"^Z5E?7E6AM
M]OM(IM-NN1[)(9&C93U*AB\9!ZD`BF*_V?95Y]VIO["S&5[G<+J6(2H/IQWA
ME19$<$`,5R.&!H&.-MB>V?95FH,L'R-XR<+>'^?:PV;LLIX-Y$XHQ)C"P5:R
MI)B22&LRMO@XJ%R%373A(ZL;,0[AVV=,S)J&%,YA3#GNEKW?AFUM@W+=]UV.
M4DPW%K/-,KIY9UC9FBD`(#HX4JU0*CKCW9Y^S=S!H<@VS9]IWZ(*L]M=00PL
MCGI[C2*JRQL02CH35:$@'IA_..+;[7%_M.0,I\>>'6+6M%X[L&%WCN5]9XUU
M"MXYE;1">XRTO'X=MY8*/M%NGZ,UC$73A_$LE(\#+IE0=J*!H,'OS]RK*V@V
MS?=VN3>[@QC-D]V[RA'HJF=,Q1$DS$!78-T.90,3NPQ=KKRXN-UV/9[46.VK
MJB]6S18L\9)80/E#N\66I9%('2C=5J9>(TT[-GO*&3;HJ6&MTE'JT;#]%L6L
M-;V&%J7*-TK!=FU4E`:3S:,O>07HK*N3-BE,V;L"G-ZIE!ERA5VWB>W;!M5)
MK",BXO;B(B2%KZ="8X#,F:,M;VX"A0YH[3$#Q..?"'?>>=;ORK?*V^YR@VNW
M6LX,5PNVVKA9+H6\F654N[MB^<H*QK;@GJH!=]5IBX^GG@,28RX8N.8P91:3
MV.T^7["&?0[VO1V3VB%U<-G%+C$'3R;Q<UL13OI5/'QF6CMQ'&73B^P<#`D"
M9NC5]TYJ.%+M,D=Q^#=4LKF`Z6;/U"SE/#4!]T/3/FZ5)Q7T>S=OOV@2;W%+
M:_CW15'C%R-7*(B`6MA)XZ)^F8ZF,*:T`(,[H*Q87[F,1WX&B?G>)IJ;M>7V
M=-=`W=OO?GIIKIUVA]1UT,]?/+7]=,-[CTE!ZK3IY9Z?/2N,,OL.XNWVC=N#
M;M\/=NU#;MT]=VOX==CZ^G76I_&PW'PJHIZ>M>GT/'&7^P\S_H_<.W_P?,[6
MG_/[>G]77'[_`$?K^GK[<M?WJX<?T3U/\WZNGLST_E4_5BD/`\AQXWA^5K^[
M['9\C=J/]X[?ZFNO^]TG]1IKJ9]+ZM:T^:O3]&%%Z75?1T]?ZV6F;^-3K^G"
MOO!\1;W+Q/!VAY'G=GQ-FX-.]Y'Z.W=I_:]->O(-?5'IL^OY9:YOFIU_1A77
MI=!O6Z?IOK9Z9?GS=/'Y<8\3[-XO^!>V>%O'_*?$\7N:!K_<_P!+?MT_CIUU
MN_6:O].U=:G\YFS4_C=<<=O^&Z'_`)5H>FK_`#63+7^)TKC9]-</L6!LWGV[
M.YH7?IIOT]=F_3UT_'37KWK3V8\&6II3-YXOZ\Q[AEC?Z=?J.&_Z+?5W>.F[
MY&^H_<[OKIK_`.IM_?\`Z]_\>IG_`)@^']/6?"O^)I?]3PQ!_P#+7Q+_`,#\
M7_X6MX_]/Q_7ATS^Q>`_[GM/M?>>>Y[_``_`\COG]P\_=^W[WD[N]W/BWZ[O
M77J+&OJ+3/JT&7QK3RIYTIX4^;$J?3:35R:-3F\,M:^]7RK7QKY^.-H39L+V
M]NS:79LTV;-`V[=/3;I^&GIIUR-:]?''84IT\,8@>W>XFT\+W;PR[].Q[CX'
M>-LW:?N?#\C737X-^OY]??WFG];2K[:5_>K3Y\?'W6K]77R^S-EK^FE?FKBA
M]N]P)N\+W7Q#]O7L>X>!W2]S9K^Y\3O[=VGP;]-?7I?>:?UM*OMI7]ZM,+[K
M5ZY=?+[,V6OZ:5^:N+93VSVYY[UX'M/CJ>X>Z>/[=XNGZOF>7^V\?;_:W_#I
M^/2BU-0:.;5KTRUK7V4ZUPIM'3;7RZ-.N:E*>VO2G[N&GH'^GGQIWZ6?1CP]
MROS-\@?(_C;^ZGW_`'WY=_2W=[9O\CUW::^NG4K?_'\R?$_69_J:NI7V9<_\
M&(C;_P`-Y)/A7H=/KGTM*GE7/D]M*U]F'F#30-NFF@::?AI^6FGIIIU#XF\1
MFYZYB<=L-Y;L%.JO&[(><N4<<@P^7H3&&"%7;NRR\NR3?13;ZX2<,RI$*Q2?
MKE0D72\J92-5!3>B8Y!(-C;)Q/D&[;3'>76X067&F)S--<T"!30_T<,9&)`J
MH"484]X`UQ6&^\QXUM&\O8VNVSWO*!0((;4G,64,*W)3(J@D!VS$JU1E+"F'
M#^VWCUSC3BE6H*=N=$O.0I:_9FO.89'&MDC+53X/,N0LM7*ZY-H4=+Q+U\T4
M6QO:YQQ`N2"<%2.8X_<(0XF*$=W`ODW#DTDT$,\-@L$$<`E4H[010I'%(0P!
MI*BB0=*484)'7$SV^L)=OXS'#=S03[DT\\EPT3!D6>29WDCJK,*Q%M-A7Z2G
MPP2N3OH1NBOK-])-W?2]C^IWR=N\GNF['M7S5Z]_O;MG9^+=KIZ]#^V_&_>^
M$>J\/>T=3P\ZY/X<3VZ?`/<^->C\1EU]/QZTRZGGXTI[<.1'^S^TMO:_;/8_
M$#Q/;_%]I\#8.WQO'_9^)V_PV_!M_AU'R:VJ=7-KUZUKFK[:]:XDX]#1&EDT
+*=*4RT]E.E,?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
